Toxicology IND Blog

Endocrine disruptors are exogenous substances that interfere with the normal function of hormonal systems, potentially causing developmental, reproductive, neurological, or immune effects in humans and wildlife. Regulatory concern over endocrine-disrupting chemicals (EDCs) has led to the implementation of structured screening and testing frameworks by agencies such as the U.S. Environmental Protection Agency (EPA) and the…

Quantitative structure–activity relationship (QSAR) modeling represents a computational method used to predict the biological activity or toxicity of chemical compounds based on their molecular structure. In regulatory toxicology, QSAR tools are increasingly employed for early hazard identification, prioritization of test compounds, and support for read-across approaches when experimental data are limited. These models provide a…

Understanding the distinction between systemic and local toxicity is a cornerstone of preclinical toxicology study design. Systemic toxicity refers to adverse effects that occur at sites distant from the point of contact or administration, typically resulting from systemic distribution through the bloodstream. In contrast, local toxicity involves direct damage at or near the site of…

Sex-based biological differences significantly influence drug metabolism, pharmacokinetics, and toxicological outcomes. While many toxicology studies historically used male animals to reduce variability, current regulatory guidance emphasizes the importance of including both sexes to detect potential sex-specific toxicities. This is particularly important for compounds affecting hormonal pathways, reproductive systems, or metabolism, where male and female animals…

Inhalation toxicology is essential for evaluating the safety of compounds delivered via respiratory exposure, whether intentionally (e.g., inhaled drugs) or incidentally (e.g., aerosols, industrial particulates). The design and interpretation of inhalation studies present unique challenges compared to oral or parenteral routes, particularly with respect to dose uniformity, particle size, and deposition patterns throughout the respiratory…

Physiologically-based pharmacokinetic (PBPK) modeling is a computational approach used to simulate the absorption, distribution, metabolism, and excretion (ADME) of compounds in humans and animals using anatomical and physiological parameters. In the context of IND submissions, PBPK models provide a powerful tool for bridging preclinical and clinical data, guiding dose selection, predicting tissue exposure, and informing…

Adverse Outcome Pathways (AOPs) represent a conceptual framework linking a molecular initiating event (MIE) to a series of biological key events (KEs) that lead to an adverse outcome (AO) at the organism or population level. This structured, mechanistic understanding of toxicity supports predictive modeling, risk assessment, and the development of alternative testing strategies. AOPs are…

Immunotoxicology is the evaluation of adverse effects on the immune system resulting from exposure to xenobiotics, including pharmaceuticals, biologics, and industrial chemicals. Given the central role of the immune system in host defense, tissue surveillance, and inflammation regulation, unintended immunosuppression or immune stimulation can have profound clinical consequences. Regulatory agencies increasingly require immunotoxicology assessments as…

Rodent bioassays have long served as the gold standard for evaluating the carcinogenic potential of pharmaceuticals, chemicals, and biologics. Chronic toxicity and carcinogenicity studies conducted in rats and mice over 18 to 24 months form the foundation of regulatory safety assessments and guide classification schemes used by global agencies. Despite their widespread use, the predictive…

Recovery groups in regulatory toxicology studies serve an essential role in evaluating the reversibility, persistence, or progression of toxicological effects after cessation of treatment. These groups typically consist of a subset of animals from the control and high-dose groups that undergo a treatment-free observation period following the primary exposure phase. Recovery phases are included in…